The abstract is read at the publisher; the summary is JClub's.
Multiplexed assays of variant effect (MAVEs) can generate functional data for thousands of variants simultaneously, improving evidence for clinical variant interpretation in germline and cancer contexts.
- Why it matters: Most genetic variants still lack sufficient evidence for pathogenic/benign classification, leaving many variants of uncertain significance unusable for diagnosis or treatment guidance, and many tumour variants’ oncogenicity remains unclear.
- What they did: The work overviews MAVE technologies from inception through increased clinical use, focusing on how massively scaled functional experiments inform variant pathogenicity mechanisms and support targeted therapy and drug development.
- The result: The review consolidates guidance on using MAVE data for classifying germline variants and highlights how MAVE-derived evidence can aid clinical implementation and therapeutic decision-making.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.